Valneva stock breaks below its €2.42 support level and continues to decline
The Lyon-based vaccine laboratory is retreating mid-morning, in a Paris market oriented downwards. The stock lost technical support during the session and extends a decline that has been underway for several weeks.
A 30-session low broken through that prolongs the stock's downward slide
The Valneva stock declines 2.75% to €2.40, while the SBF 120 loses 1.49% and the CAC 40 falls 1.53%. The stock broke through its lowest level of the last 30 sessions during the session, at €2.42, a level that has become resistance and which it has not reclaimed. This decline adds to a loss of 15.74% over one month, following the withdrawal of Ixchiq authorization in the United Kingdom, announced on October 7.
The price is below all three moving averages: 6.46% below the 20-day MA, 12.26% below the 50-day MA and 19.60% below the 200-day MA. The RSI at 39 remains neutral.
A trajectory that remains tied to the regulatory agenda for the Lyme disease vaccine
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In their latest financial statement, published with H1 2026 results on August 13, Valneva's teams indicated that regulatory decisions on the LB6V vaccine candidate against Lyme disease were expected within 12 months. The group also confirmed its outlook for 2026, despite the persistent impact of the geopolitical context on travel. These topics will be on the agenda of the investor conferences announced on October 14, between Paris, Boston, New York and London.
In its sector, Sanofi loses 0.87% today and 1.96% over one month. The next technical level to watch for Valneva is the support at €2.08.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
